Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care? Arjan C. Lankester, Franco Locatelli, Peter Bader, Eva Rettinger,

Slides:

Advertisements

Similar presentations

Survival in a Recent Cohort of Mechanically Ventilated Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients Josephus P.J. van Gestel,

Advertisements

Significant Transplantation-Related Mortality from Respiratory Virus Infections within the First One Hundred Days in Children after Hematopoietic Stem.

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation Navneet S. Majhail, MD, MS, Tejo.

Rakesh K. Goyal, Kelong Han, Donna A. Wall, Michael A

How to Treat MDS without Stem Cell Transplantation

Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma?

Vaccination of Children following Allogeneic Stem Cell Transplantation

Reduced-Intensity Conditioning Hematopoietic Cell Transplantation Is an Effective Treatment for Patients with SLAM-Associated Protein Deficiency/X-linked.

Survival in a Recent Cohort of Mechanically Ventilated Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients Josephus P.J. van Gestel,

Allogeneic Stem Cell Transplantation in Myelofibrosis

Individualized Dosing and Therapeutic Drug Monitoring (TDM) of ATG is Feasible, Safe, Effective, and Associated with Excellent Immune Reconstitution

NCI, NHLBI/PBMTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Endocrine Challenges—Thyroid Dysfunction,

NCI, NHLBI/PBMTC First International Conference on Late Effects After Pediatric Hematopoietic Cell Transplantation: Persistent Immune Deficiency in Pediatric.

Sabina Kersting, Leo F. Verdonck

Access to Hematopoietic Cell Transplantation in the United States

The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.

Viral PCR Positivity in Stool before Allogeneic Hematopoietic Cell Transplantation Is Strongly Associated with Acute Intestinal Graft-versus-Host Disease

Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation in Children Coco de Koning, Maud Plantinga, Paul Besseling, Jaap Jan Boelens,

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

Stem Cell Transplant for Children with Sickle Cell Anemia: Parent and Patient Interest Michael Roth, Julie Krystal, Deepa Manwani, Catherine Driscoll,

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model Justin N. Baker,

Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma Peter Dreger, Ginna.

The Other Face of Chimeric Antigen Receptors

Relating Autoimmune Cytopenias after Hematopoietic Cell Transplantation (HCT) to Transplant-Variables and Immune Reconstitution: A Predictor Analysis

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Hematopoietic Cell Transplantation for Mucopolysaccharidosis Patients Is Safe and Effective: Results after Implementation of International Guidelines

The Influence of Stem Cell Source on Chronic-GvHD Free, Leukemia Free Transplant Survival in Pediatric Patients with Acute Myeloid Leukemia Amy K. Keating,

Visualizing the Immune Synapse

Research Techniques Made Simple: CAR T-Cell Therapy

Donor Selection in T Cell–Replete Haploidentical Hematopoietic Stem Cell Transplantation: Knowns, Unknowns, and Controversies Stefan O. Ciurea, Richard.

Impact of Conditioning Regimen in Allogeneic Hematopoetic Stem Cell Transplantation for Children with Acute Myelogenous Leukemia beyond First Complete.

Cell-Based Therapy Using Umbilical Cord Blood for Novel Indications in Regenerative Therapy and Immune Modulation: An Updated Systematic Scoping Review.

B Cells and Transplantation: An Educational Resource

Kamal Kant Singh Abbi, Junting Zheng, Sean M

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Eva Guinan, Leo Luzmik, Rupert Handgretinger, Ann Woolfrey

Early CD4+ Immune Reconstitution Predicts Probability of Relapse in Pediatric AML after Unrelated Cord Blood Transplantation: Importance of Preventing.

TNF-Receptor Inhibitor Therapy for the Treatment of Children with Idiopathic Pneumonia Syndrome. A Joint Pediatric Blood and Marrow Transplant Consortium.

NCI, NHLBI/PBMTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Health-Related Quality of Life, Functional,

Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse Saad S. Kenderian, David L. Porter,

Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis Jason.

Two Partial T Cell Depletion Strategies for Unrelated Donor Peripheral Stem Cell Transplantation are Associated with Excellent Outcomes for Pediatric.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Pauline Damien, David S. Allan

Gerard Socié, K. Scott Baker, Smita Bhatia

What is quality in a transplant program?

Chimeric antigen receptor T-cell therapy for solid tumors

by Shannon L. Maude, David T. Teachey, David L. Porter, and Stephan A

Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution William B. Ershler, Andrew S. Artz, Evan T. Keller

Participation in Clinical Research: Perspectives of Adult Patients and Parents of Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation

Competitive TNF Inhibitor (ETANERCEPT) for the Treatment of Idiopathic Pneumonia Syndrome (IPS) Following Allogeneic Stem Cell Transplantation (SCT).

Treosulfan-Thiotepa-Fludarabine–Based Conditioning Regimen for Allogeneic Transplantation in Patients with Thalassemia Major: A Single-Center Experience.

Management of Cytokine Release Syndrome (CRS) in Patients Undergoing Chimeric Antigen Receptor Modified (CAR) T-Cell Therapy Following Autologous Stem.

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Brigitte T. A. van den Broek, Mieke Aldenhoven, Robert F

Blood and Marrow Transplant Handbook

Bernard Maybury, Gordon Cook, Guy Pratt, Kwee Yong, Karthik Ramasamy

Thymoglobulin® Exposure Is Influencing CD4+ Immune Reconstitution As a Predictor for Improved Overall Survival in Pediatric Haematopoietic Cell Transplantation:

Molecular Therapy Volume 21, Pages S247-S248 (May 2013)

Mammen Chandy Biology of Blood and Marrow Transplantation

Early and Late Extensive Chronic Graft-versus-Host Disease in Children Is Characterized by Different Th1/Th2 Cytokine Profiles: Findings of the Children's.

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Treatment versus Transplant for Challenging Hematologic Disorders

Fig. 1 Engineered T cells: design of TCR versus CAR T cells.

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

In Memoriam: E. Donnall Thomas

Prediction of Area under the Cyclosporine Concentration Versus Time Curve in Children Undergoing Hematopoietic Stem Cell Transplantation L. Lee Dupuis,

Presentation transcript:

Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care? Arjan C. Lankester, Franco Locatelli, Peter Bader, Eva Rettinger, Maarten Egeler, Satyendra Katewa, Michael A. Pulsipher, Stefan Nierkens, Kirk Schultz, Rupert Handgretinger, Stephan A. Grupp, Jaap Jan Boelens, Catherine M. Bollard Biology of Blood and Marrow Transplantation Volume 21, Issue 3, Pages 402-411 (March 2015) DOI: 10.1016/j.bbmt.2014.07.018 Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 A CAR consists of a single chain variable fragment of an antibody (scFv) that recognizes a protein (such as CD19 on B cells and ALL cells) coupled to the CD3 ζ activation domain and costimulatory domains from CD28 and/or 4-1BB. This combines the MHC-independent recognition of a tumor antigen with the activating potential of T cell receptor signaling, allowing for redirection of T cells to cancer cells and extensive in vivo proliferation. © Sue Seif. Reproduced with permission. Biology of Blood and Marrow Transplantation 2015 21, 402-411DOI: (10.1016/j.bbmt.2014.07.018) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions